Efficacy of Bezlotoxumab in Participants Receiving Metronidazole Vancomycin or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection

摘要

In phase 3 MODIFY I/II trials, bezlotoxumab significantly reduced recurrence of ( ) infection (rCDI) over 12 weeks. Choice of CDI antibacterial treatment may affect CDI-related outcomes; therefore, this prespecified analysis assessed if the magnitude of bezlotoxumab-induced rCDI reduction was influenced by the antibiotic administered.